Related Experiment Video
Updated: Mar 26, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Myeloid Acyl-CoA:Cholesterol Acyltransferase 1 Deficiency Reduces Lesion Macrophage Content and Suppresses
Li-Hao Huang1, Elaina M Melton1, Haibo Li1
1From the Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire 03755 and.
Abstract:
Acyl-CoA:cholesterol acyltransferase 1 (Acat1) converts cellular cholesterol to cholesteryl esters and is considered a drug target for treating atherosclerosis. However, in mouse models for atherosclerosis, global Acat1 knockout (Acat1(-/-)) did not prevent lesion development. Acat1(-/-) increased apoptosis within lesions and led to several additional undesirable phenotypes, including hair loss, dry eye, leukocytosis, xanthomatosis, and a reduced life span. To determine the roles of Acat1 in monocytes/macrophages in atherosclerosis, we produced a myeloid-specific Acat1 knockout (Acat1(-M/-M)) mouse and showed that, in the Apoe knockout (Apoe(-/-)) mouse model for atherosclerosis, Acat1(-M/-M) decreased the plaque area and reduced lesion size without causing leukocytosis, dry eye, hair loss, or a reduced life span. Acat1(-M/-M) enhanced xanthomatosis in apoe(-/-) mice, a skin disease that is not associated with diet-induced atherosclerosis in humans. Analyses of atherosclerotic lesions showed that Acat1(-M/-M) reduced macrophage numbers and diminished the cholesterol and cholesteryl ester load without causing detectable apoptotic cell death. Leukocyte migration analysis in vivo showed that Acat1(-M/-M) caused much fewer leukocytes to appear at the activated endothelium. Studies in inflammatory (Ly6C(hi)-positive) monocytes and in cultured macrophages showed that inhibiting ACAT1 by gene knockout or by pharmacological inhibition caused a significant decrease in integrin β 1 (CD29) expression in activated monocytes/macrophages. The sparse presence of lesion macrophages without Acat1 can therefore, in part, be attributed to decreased interaction between inflammatory monocytes/macrophages lacking Acat1 and the activated endothelium. We conclude that targeting ACAT1 in a myeloid cell lineage suppresses atherosclerosis progression while avoiding many of the undesirable side effects caused by global Acat1 inhibition.
Insights
Targeting Acyl-CoA:cholesterol acyltransferase 1 (Acat1) in myeloid cells reduces atherosclerosis progression. This myeloid-specific approach avoids the severe side effects seen with global Acat1 knockout, offering a promising therapeutic strategy.
Area of Science:
- Biomedical Science
- Cardiovascular Research
- Immunology
Background:
- Acyl-CoA:cholesterol acyltransferase 1 (Acat1) plays a role in cholesterol metabolism and is a potential drug target for atherosclerosis.
- Global Acat1 knockout in mice did not prevent atherosclerosis and caused detrimental side effects, including increased apoptosis and reduced lifespan.
- The specific role of Acat1 in myeloid cells, particularly monocytes and macrophages, within atherosclerosis remained unclear.
Purpose of the Study:
- To investigate the specific role of Acat1 in myeloid cells during atherosclerosis development.
- To evaluate the efficacy and safety of targeting Acat1 in a myeloid-specific manner for atherosclerosis treatment.
- To elucidate the mechanisms by which Acat1 influences leukocyte behavior and lesion progression in atherosclerosis.
Main Methods:
- Generation of a myeloid-specific Acat1 knockout (Acat1(-M/-M)) mouse model.
- Utilized the Apoe knockout (Apoe(-/-)) mouse model for atherosclerosis.
- Analyzed atherosclerotic lesions, leukocyte migration in vivo, and performed studies on isolated monocytes and macrophages.
Main Results:
- Myeloid-specific Acat1 knockout (Acat1(-M/-M)) in Apoe(-/-) mice significantly decreased plaque area and lesion size.
- Acat1(-M/-M) reduced macrophage infiltration and cholesterol/cholesteryl ester load in lesions without increasing apoptosis.
- Inhibition of Acat1 reduced integrin β1 (CD29) expression on monocytes/macrophages, impairing their interaction with the endothelium.
Conclusions:
- Targeting Acat1 within myeloid cells effectively suppresses atherosclerosis progression.
- Myeloid-specific Acat1 inhibition avoids the adverse systemic effects associated with global Acat1 knockout.
- Reduced leukocyte-endothelial interaction, due to decreased integrin β1 expression, is a key mechanism by which Acat1 deficiency impacts atherosclerosis.
Related Concept Videos
Inflammation
Atherosclerosis I: Introduction
Coronary Artery Disease II: Pathophysiology
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

